This site is no longer being updated. Data are accurate as of 2 Dec 2022.

Center for Genetic Engineering and Biotechnology (CIGB): Abdala

Center for Genetic Engineering and Biotechnology (CIGB): Abdala

Vaccine Type: Protein Subunit

This vaccine may also be referred to as CIGB-66

About Trial Phases

Phase 1: 2 Trials

RPCEC00000345
Cuba
RPCEC00000346
Cuba

Phase 2: 2 Trials

RPCEC00000345
Cuba
RPCEC00000346
Cuba

Phase 3: 1 Trial

RPCEC00000359
Cuba

Approvals

6 Countries

Registered Trials

RPCEC00000359
Phase 3
Cuba
Total Enrollment: 48,000
Official Trial Registration:
- RPCEC00000359(Opens in new tab/window)
RPCEC00000345
Phase 1/2
Cuba
Total Enrollment: 88
Official Trial Registration:
- RPCEC00000345(Opens in new tab/window)
RPCEC00000346
Phase 1/2
Cuba
Total Enrollment: 132
Official Trial Registration:
- RPCEC00000346(Opens in new tab/window)

© 2023 VIPER Group COVID19 Vaccine Tracker Team

Funding provided by the McGill University Interdisciplinary Initiative in Infection and Immunity (MI4)

This site is provided for informational purposes only based on publically available data.

Site Credits Website Feedback Form